ZMAT3

Across TCGA pan-cancer cohorts, ZMAT3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZMAT3 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZMAT3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZMAT3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LSCC, and GBM are the cancer types where ZMAT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.470	0.264	.038	5	view →
LSCC	DFS	Median	All	0.485	0.840	.025	5	view →
GBM	OS	Quartile	All	0.623	0.452	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZMAT3–PDAC (DFS)

Open the PDAC breakdown →